Abciximab prevents ischemic complications during angioplasty
The EPILOG Trial
Cleveland Clinic Journal of Medicine. 1998 May;65(5):267-272
May 1, 1998|Cleveland Clinic Journal of Medicine
Author and Disclosure Information
ABSTRACT
The EPILOG trial showed that the platelet glycoprotein IIb/IIIa inhibitor abciximab, together with heparin in a low, weight-adjusted dose, markedly reduced the risk of acute ischemic complications during percutaneous coronary revascularization, without increasing the risk of hemorrhage.
